ClinicalTrials.gg

Program

JXL-069

Its studies are mostly in Alopecia, led by Pelage Pharmaceuticals.

Furthest: phase 3, since Sep 9, 20263 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pelage Pharmaceuticals32 open or runningphase 3since Sep 9, 2026Apr 26, 2024Sep 2027phase 2 · NCT07907783

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2024First study: phase 2 study in AlopeciaFirst studyNCT06393452 · 78 enrolled · United States
  2. Sep 9, 2026Phase 3 study in AlopeciaPhase 3 reachedNCT07819435 · 600 planned · United States, Canada
  3. Oct 24, 2026Phase 2 study in AlopeciaNCT07907783 · 200 planned

Ahead

  1. Sep 2027Primary completion: phase 2 study in AlopeciaNCT07907783
  2. Dec 2027Primary completion: phase 3 study in AlopeciaNCT07819435

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07907783Alopecia2Not yet recruitingSep 2027200
NCT07819435Alopecia · United States, Canada3RecruitingDec 2027600
NCT06393452Alopecia · United States2CompletedJul 16, 202578

How it is read

Names in the registry

  • “PP405 0.05% Topical Gel”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
JXL-069 (Pelage Pharmaceuticals): development program | ClinicalTrials.gg